A PHASE 3, SINGLE-ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF FINERENONE IN ADDITION TO STANDARD OF CARE, IN PEDIATRIC HEART FAILURE PATIENTS, FROM BIRTH TO 18 YEARS OF AGE, WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVSD)
- Registry ID
- 21467
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- BAYER INC
- Start date
- 2026-06-02
- Last update
- 2025-08-29
Conditions
Related clinical trials
- EFFICACY AND SAFETY OF NNC0487-0111 COMPARED TO PLACEBO ON MORBIDITY AND MORTALITY IN PEOPLE WITH HEART FAILURE WITH PRESERVED OR MILDLY REDUCED EJECTION FRACTION AND OBESITY (HF-POLARIS)
- A MULTI-CENTER, RANDOMIZED, PARTICIPANT- AND INVESTIGATOR- BLINDED, PLACEBO-CONTROLLED CROSSOVER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF HJB647 IN PARTICIPANTS WITH CHRONIC STABLE HEART FAILURE WITH REDUCED OR MILDLY REDUCED EJECTION FRACTION (HFREF/HFMREF)
- ORAL L-CARNITINE SUPPLEMENTATION IN CARDIORENAL HEART FAILURE PATIENTS
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND PK/ PD OF FINERENONE, IN ADDITION TO STANDARD-OF-CARE, IN PEDIATRIC PATIENTS, 6 MONTHS TO < 18 YEARS OF AGE WITH HEART FAILURE (HF) AND LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVSD)
- A PHASE 2, MULTICENTER, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE EFFECTS
OF SOTATERCEPT FOR THE TREATMENT OF COMBINED POSTCAPILLARY AND PRECAPILLARY
PULMONARY HYPERTENSION (CPC-PH) DUE TO HEART FAILURE WITH PRESERVED
EJECTION FRACTION (HFPEF)
- A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO ASSESS EFFICACY AND SAFETY OF OMECAMTIV MECARBIL IN PATIENTS WITH SYMPTOMATIC HEART
FAILURE WITH SEVERELY REDUCED EJECTION FRACTION
View on source registry